Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
← CataloguePlate I of XXX
IPlate IReviewed 2026-04-25

5-Amino-1MQ

NNMT Inhibitor (small molecule)

also known as 5-Amino-1-Methylquinolinium, 5A-1MQ

Selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obesity that consumes SAM and NAD+. Inhibition restores cellular methylation and energy balance. Animal studies (Neelakantan 2018) showed reversal of high-fat-diet-induced obesity in mice. Listed for class completeness; not a peptide.

§ I

At a glance

Daily dose (oral)
100–200 mg
[neelakantan-2018-namq]
Evidence level
Animal
[neelakantan-2018-namq]
Half-life (est)
Hours
Route

Oral · Once daily fasted

§ II

Mechanism

Primary target — Nicotinamide N-methyltransferase (NNMT) [neelakantan-2018-namq].

Pathway — NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expression [neelakantan-2018-namq].

Downstream effect — Reversal of HFD-induced obesity in murine models; improved metabolic profile [neelakantan-2018-namq].

Origin — Selective small-molecule inhibitor designed in academic medicinal chemistry programs [neelakantan-2018-namq].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

ParameterValue
Standard dose100–200 mg / day oral [neelakantan-2018-namq]Anecdotal community range; murine doses scaled.
FrequencyOnce daily, fasted
Lower / starter dose50 mg / day
Evidence basisAnimal-strong; no human RCT data [neelakantan-2018-namq]
Duration8–12 weeks per cycle
FormOral capsule
TimingMorning fasted preferred
Half-lifeHours (estimated; no human PK published)
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to 5-Amino-1MQ's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
≈ 10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

GI symptomsmild
Mild nausea (anecdotal)
Methylation disruptionmoderate
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
Long-term safetymoderate
Unknown — no human trials
Cancer riskmoderate
Unclear — NNMT also studied in oncology contexts
Pregnancy / OBsevere
Avoid
Drug interactionsmoderate
Theoretical with niacin / B-vitamin supplements
Absolute contraindications
  • — Pregnancy / breastfeeding
  • — Active malignancy
Relative contraindications
  • — Methylation-sensitive conditions (MTHFR mutation)
  • — Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
§ VI

Administration

  1. 01
    Form

    Oral capsule. No injection.

  2. 02
    Administration

    Take with water, fasted preferred.

  3. 03
    Timing

    Morning fasted.

  4. 04
    Storage

    Room temp ≤25 °C, dry place.

  5. 05
    Caveat

    Monitor B-vitamin status with chronic use.

Appendix

Sources

21%

of 38 rendered claims carry a resolvable citation.

  1. [neelakantan-2018-namq]
    Neelakantan 2018 — Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
    Biochem Pharmacol, 2018
    PubMed →
Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 30 fields uncited — open contributions
Edit on GitHub →Read another →